KLK3 and prostate carcinoma: In studies conducted with humans, Guess et al. [163] evaluated the effect of modified citrus pectin (Pecta-Sol® (Santa Rosa, CA, USA) in patients with prostate cancer showing that modified citrus pectin (MPC) can increase prostate-specific antigen (PSA) doubling time in 7 of 10 men (with biochemical recurrence of prostate cancer following local therapy) after taking MCP for 12 months, compared with before the take of MCP.